<DOC>
	<DOCNO>NCT00550680</DOCNO>
	<brief_summary>This single-arm study ass efficacy safety intravenous ( IV ) Mircera administer maintenance hemoglobin ( Hb ) level participant chronic renal anemia . Individuals currently receive maintenance treatment epoetin alfa darbepoetin alfa receive monthly injection Mircera , start dose ( 120 , 200 , 360 microgram [ mcg ] IV injection ) derive dose epoetin alfa darbepoetin alfa receive week precede study start .</brief_summary>
	<brief_title>A Study Mircera Maintenance Treatment Participants With Chronic Renal Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<criteria>Adults great equal ( ≥ ) 18 year age Chronic renal anemia Stable epoetin alfa darbepoetin alfa therapy past 2 month Hemodialysis therapy ≥3 month Transfusion red blood cell previous 2 month Poorly control hypertension require hospitalization interruption ESA treatment previous 6 month Acute chronic bleeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>